Johnson & Johnson Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
Johnson & Johnson (JNJ) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax of $218.00 million for the 12-month period ending 2018-12-30, per its 10-K filed 2019-02-20.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax · last filed 2019-02-20
- Johnson & Johnson other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2018-12-30 was $112.00M.
- Johnson & Johnson other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2018-09-30 was -$50.00M.
- Johnson & Johnson other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2017-12-31 was -$68.00M.
- Johnson & Johnson other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2017-10-01 was -$151.00M.
- Johnson & Johnson other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2018 was $218.00M.
- Johnson & Johnson other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2017 was -$597.00M.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 12 month |
|---|---|---|---|---|
| 2018-12-30 | $112.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $62.00M derived: sum of 2 quarters · filed 2019-02-20 | $218.00M 10-K · filed 2019-02-20 | |
| 2018-09-30 | -$50.00M 10-Q · filed 2018-10-31 | $106.00M 10-Q · filed 2018-10-31 | ||
| 2017-12-31 | -$68.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$219.00M derived: sum of 2 quarters · filed 2019-02-20 | -$597.00M 10-K · filed 2019-02-20 | |
| 2017-10-01 | -$151.00M 10-Q · filed 2018-10-31 | -$529.00M 10-Q · filed 2018-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |